

CONFIRMATORY ASSIGNMENT

Roche Glycart AG ("ASSIGNOR") a corporation duly organized under the laws of Switzerland and having its principal place of business at Wagistrasse 10, CH-8952 Schlieren, Switzerland

acknowledges the previous transfer to

F. Hoffmann-La Roche AG ("ASSIGNEE") a corporation duly organized under the laws of Switzerland, and having its principal place of business at 124 Grenzacherstrasse, CH-4070 Basle, Switzerland

for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, of all right, title, and interest in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below for all countries of the world by operation of law, contract, or otherwise, and any Letters Patent which may hereafter be granted on the same in all countries of the world including any application claiming priority, divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof.

As far as the right, title, and interest of ASSIGNOR in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below may not have been transferred, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers to ASSIGNEE, and to ASSIGNEE'S successors and assigns, for all countries of the world all of ASSIGNOR'S right, including the right to claim priority, title and interest in, to, and deriving from the invention(s) described in the patent application(s) listed below, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, or other patent applications claiming the benefit of the filing date of the following patent application(s):

Case No.	Country	Filing Date	Serial No.
P37162-EP	Europe	14 October 2021	21202553.0

entitled

New Interleukin-7 Immunoconjugates

ASSIGNEE, by virtue of this Assignment, shall have the right to file and own patent applications that claim priority to and are based in whole or in part on the patent application(s) cited above in all countries of the world and to own Letters Patents that issue thereon. Accordingly, ASSIGNOR hereby authorizes and requests the patent offices to issue any Letters Patent which may issue for such patent applications, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and ASSIGNOR further agrees that he will, without charge to said ASSIGNEE, but at ASSIGNEE'S expense, cooperate with ASSIGNEE in the prosecution of said Letters Patent and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as ASSIGNEE lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said ASSIGNEE, or ASSIGNEE'S successors and assigns.

Case Record No. P37162-EP

This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

ASSIGNOR

Roche Glycart AG

Basel, 26.4.2022
Place, Date

Amann J. Gengelbach
Signatures
Susanne Amann Ina Gengelbach
duly authorized signatory duly authorized signatory

ASSIGNEE

F. Hoffmann-La Roche AG

26.04.2022
Basel, Date

Antonio Natoli Petra Querfeld
Antonio Natoli Petra Querfeld
Holder of procuration Mandatory

ASSIGNMENT AGREEMENT

Roche Diagnostics GmbH ("ASSIGNOR") a corporation duly organized under the laws of Germany and having its principal place of business at Sandhofer Strasse 116, D-68305 Mannheim, Germany

acknowledges the transfer to

F. Hoffmann-La Roche AG ("ASSIGNEE") a corporation duly organized under the laws of Switzerland, and having its principal place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland

for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, of all right, title, and interest in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below and its possessions by operation of law, contract, or otherwise, and any Letters Patent which may hereafter be granted on the same including any application claiming priority, divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof.

As far as the right, title, and interest of ASSIGNOR in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below may not have been transferred, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers to ASSIGNEE, and to ASSIGNEE'S successors and assigns, all of ASSIGNOR'S right, including the right to claim priority, title and interest in, to, and deriving from the invention(s) described in the patent application(s) listed below, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, or other patent applications claiming the benefit of the filing date of the following patent application(s):

Case No.	Country	Filing Date	Serial No.
P37162-EP	Europe	14 October 2021	21202553.0

entitled

New Interleukin-7 Immunoconjugates

ASSIGNEE, by virtue of this Assignment, shall have the right to file and own patent applications that claim priority to and are based in whole or in part on the patent application(s) cited above and to own Letters Patents that issue thereon. Accordingly, ASSIGNOR hereby authorizes and requests to issue any Letters Patent which may issue for such patent applications, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and ASSIGNOR further agrees that he will, without charge to said ASSIGNEE, but at ASSIGNEE'S expense, cooperate with ASSIGNEE in the prosecution of said Letters Patent and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as ASSIGNEE lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said ASSIGNEE, or ASSIGNEE'S successors and assigns.

Case No. P37162-EP

This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

ASSIGNOR

Roche Diagnostics GmbH

Basel, 08 June 2022 Am. An. F. Iskender
Place, Date Signatures
Dina Van Dam Funda Iskender
duly authorized signatory duly authorized signatory

ASSIGNEE

F. Hoffmann-La Roche AG

Basel, 09 June 2022 Antonio Natoli N. Querfeld
Place, Date Signatures
Antonio Natoli Petra Querfeld
Holder of procuration Mandatory

CONFIRMATORY ASSIGNMENT

I/We, the undersigned

Inventor(s)

Johann KOLL, a German citizen
c/o Roche Diagnostics GmbH
Nonnenwald 2
82377 Penzberg, Germany

Alejandro CARPY GUTIERREZ CIRLOS, a German citizen
c/o Roche Diagnostics GmbH
Nonnenwald 2
82377 Penzberg, Germany

Employed by:

Roche Diagnostics GmbH

Roche Diagnostics GmbH

hereinafter ASSIGNOR(S), herewith declare that I am/we are joint inventor(s) together with

Inventor(s)

Anne FREIMOSER-GRUNDSCHOBEN
Christian KLEIN
Pablo UMAÑA
Ekkehard MOESSNER
Laura CODARRI DEAK
Laura LAUENER
Cindy SCHULENBURG
Valeria NICOLINI
Greta DURINI

Employed by:

Roche Glycart AG
Roche Glycart AG
Roche Glycart AG
Roche Glycart AG
Roche Glycart AG
Roche Glycart AG
Roche Glycart AG
Roche Glycart AG
Roche Glycart AG

hereinafter CO-INVENTOR(S)

of the invention entitled:

New Interleukin-7 Immunoconjugates

for which (a) priority application(s) was (were) filed with the

European Patent Office

as outlined below:

Case No.	Country	Filing Date	Serial No.
P37162-EP	Europe	14 October 2021	21202553.0

ASSIGNOR(S) acknowledge(s) the previous transfer to

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim
Germany

hereinafter ASSIGNEE, of all right, title, and interest in, to, and deriving from the inventions disclosed in the priority application(s) set forth above by operation of law, contract, or otherwise.

As far as right, title, and interest of the ASSIGNOR(S) in, to, and deriving from the inventions disclosed in the patent application(s) set forth above may not have been transferred to ASSIGNEE, ASSIGNOR(S) herewith assign(s) to ASSIGNEE all right, title, and interest in, to, and deriving from the invention and to the above priority application(s), including the right to claim priority.

The assignment of the rights of the CO-INVENTOR(S) is subject to a separate assignment agreement. ASSIGNOR(S) explicitly approve(s) that assignment.

ASSIGNEE by virtue of this assignment thereof shall have the exclusive right and is fully entitled to claim priority of the priority application(s) set forth above, to apply for, obtain, and own patents worldwide in its own name and at its own costs that claim priority to and are based in whole or in part on the priority application(s), to maintain any patent granted thereupon and to discontinue any patents or patent applications as it deems appropriate.

ASSIGNOR(S)

Schwabhausen, 02.05.2022 Johann KOLL
Place, Date

Place, Date

Alejandro CARPY GUTIERREZ CIRLOS

ASSIGNEE

Roche Diagnostics GmbH

Basel, 30.5.2022 Dina van Dam Funda Iskender
Place, Date
duly authorized signatory duly authorized signatory

CONFIRMATORY ASSIGNMENT

I/We, the undersigned

Inventor(s)

Johann KOLL, a German citizen
c/o Roche Diagnostics GmbH
Nonnenwald 2
82377 Penzberg, Germany

Employed by:

Roche Diagnostics GmbH

Alejandro CARPY GUTIERREZ CIRLOS, a German citizen
c/o Roche Diagnostics GmbH
Nonnenwald 2
82377 Penzberg, Germany

Roche Diagnostics GmbH

hereinafter ASSIGNOR(S), herewith declare that I am/we are joint inventor(s) together with

Inventor(s)

Anne FREIMOSER-GRUNDSCHOBEN
Christian KLEIN
Pablo UMAÑA
Ekkehard MOESSNER
Laura CODARRI DEAK
Laura LAUENER
Cindy SCHULENBURG
Valeria NICOLINI
Greta DURINI

Employed by:

Roche Glycart AG
Roche Glycart AG
Roche Glycart AG
Roche Glycart AG
Roche Glycart AG
Roche Glycart AG
Roche Glycart AG
Roche Glycart AG
Roche Glycart AG

hereinafter CO-INVENTOR(S)

of the invention entitled:

New Interleukin-7 Immunoconjugates

for which (a) priority application(s) was (were) filed with the

European Patent Office

as outlined below:

Case No.	Country	Filing Date	Serial No.
P37162-EP	Europe	14 October 2021	21202553.0

ASSIGNOR(S) acknowledge(s) the previous transfer to

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim
Germany

hereinafter ASSIGNEE, of all right, title, and interest in, to, and deriving from the inventions disclosed in the priority application(s) set forth above by operation of law, contract, or otherwise.

As far as right, title, and interest of the ASSIGNOR(S) in, to, and deriving from the inventions disclosed in the patent application(s) set forth above may not have been transferred to ASSIGNEE, ASSIGNOR(S) herewith assign(s) to ASSIGNEE all right, title, and interest in, to, and deriving from the invention and to the above priority application(s), including the right to claim priority.

the assignment of the rights of the CO-INVENTOR(S) is subject to a separate assignment agreement. ASSIGNOR(S) explicitly approve(s) that assignment.

ASSIGNEE by virtue of this assignment thereof shall have the exclusive right and is fully entitled to claim priority of the priority application(s) set forth above, to apply for, obtain, and own patents worldwide in its own name and at its own costs that claim priority to and are based in whole or in part on the priority application(s), to maintain any patent granted thereupon and to discontinue any patents or patent applications as it deems appropriate.


ASSIGNOR(S)

Place, Date

Munich, 01.03.2022

Place, Date

Johann KOLL



Alejandro CARPY GUTIERREZ CIRLOS

ASSIGNEE

Roche Diagnostics GmbH

Place, Date

Basel, April 01, 2022

Ina Gengelbach
duly authorized signatory

Petra Querfeld
duly authorized signatory

CONFIRMATORY ASSIGNMENT

I/We, the undersigned

Inventor(s)

Laura CODARRI DEAK, a Swiss citizen
c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren
Switzerland

Greta DURINI, a Swiss citizen
c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren
Switzerland

Anne FREIMOSER-GRUNDSCHOBBER, a Swiss citizen
c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren
Switzerland

Christian KLEIN, A German citizen
c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren
Switzerland

Laura LAUENER, a Swiss citizen
c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren
Switzerland

Ekkehard MOESSNER, a German citizen
c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren
Switzerland

Valeria NICOLINI, a Spanish citizen
c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren
Switzerland

Cindy SCHULENBURG, a German citizen
c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren
Switzerland

Pablo UMAÑA, a Spanis citizen
c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren
Switzerland

Employed by:

Roche Glycart AG

Roche Glycart AG

Roche Glycart AG

Roche Glycart AG

Roche Glycart AG

Roche Glycart AG

Roche Glycart AG

Roche Glycart AG

Roche Glycart AG

hereinafter ASSIGNOR(S), herewith declare that I am/we are joint inventor(s) together with

Inventor(s)

Johann KOLL
Alejandro CARPY GUTIERREZ CIRLOS

Employed by:

Roche Diagnostics GmbH
Roche Diagnostics GmbH

hereinafter CO-INVENTOR(S)

of the invention entitled:

New Interleukin-7 Immunoconjugates

for which (a) priority application(s) was (were) filed with the

European Patent Office

as outlined below:

Case No.
P37162-EPCountry
EuropeFiling Date
14 October 2021Serial No.
21202553.0

ASSIGNOR(S) acknowledge(s) the previous transfer to

Roche Glycart AG
Wagistrasse 10
8952 Schlieren
Switzerland

hereinafter ASSIGNEE, of all right, title, and interest in, to, and deriving from the inventions disclosed in the priority application(s) set forth above by operation of law, contract, or otherwise.

As far as right, title, and interest of the ASSIGNOR(S) in, to, and deriving from the inventions disclosed in the patent application(s) set forth above may not have been transferred to ASSIGNEE, ASSIGNOR(S) herewith assign(s) to ASSIGNEE all right, title, and interest in, to, and deriving from the invention and to the above priority application(s), including the right to claim priority.






The assignment of the rights of the CO-INVENTOR(S) is subject to a separate assignment agreement. ASSIGNOR(S) explicitly approve(s) that assignment.

ASSIGNEE by virtue of this assignment thereof shall have the exclusive right and is fully entitled to claim priority of the priority application(s) set forth above, to apply for, obtain, and own patents worldwide in its own name and at its own costs that claim priority to and are based in whole or in part on the priority application(s), to maintain any patent granted thereupon and to discontinue any patents or patent applications as it deems appropriate.

ASSIGNEE and ASSIGNOR hereby acknowledge, confirm, and agree that ASSIGNOR has been fully and adequately compensated for all rights granted or assigned to ASSIGNEE hereunder.

This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

ASSIGNOR(S)

16.02.2022	
Schlieren, Date	Laura CODARRI DEAK
01.02.2022	
Schlieren, Date	Greta DURINI
05.03.2022	
Schlieren, Date	Anne FREIMOSER-GRUNDSCHÖBER
8.3.2022	
Schlieren, Date	Christian KLEIN
12.03.2022	
Schlieren, Date	Laura LAUENER
15.3.2022	
Schlieren, Date	Ekkehard MOESSNER
17.03.2022	
Schlieren, Date	Valeria NICOLINI
19.03.2022	
Schlieren, Date	Cindy SCHULENBURG
28/3/2022	
Schlieren, Date	Pablo UMANA

ASSIGNEE

Roche Glycart AG

Basel, 18.4.22
Place, Date

Amann
Susanne Amann
duly authorized signatory

J. Gengelbach
Ina Gengelbach
duly authorized signatory